Combined Anticoagulant Therapy for Prevention of Preeclampsia and Small for Gestational Age Neonates: A Systematic Review and Meta-analysis

 

 Buy Article Permissions and Reprints

Abstract

Objective This systematic review and meta-analysis (SRMA) aims to compare the efficacy of combining low molecular weight heparin (LMWH) and aspirin against aspirin alone in preventing preeclampsia (PE) and small for gestational age (SGA) neonates in women at moderate and high risks.

Study Design The included studies were nonrandomized and randomized clinical trials (RCTs) enrolling women at moderate and high risks for developing preeclampsia. PubMed/Medline, Cochrane Library, Embase, and Grey literature (including ClinicalTrials.gov) were searched.

Results Out of 4,762 records, 7 nonrandomized studies and 12 RCTs (enrolling 545 and 1,677 women, respectively) were selected. Although the studies were clinically heterogeneous, the conduction of quantitative analysis was feasible. Regarding RCTs, the odds of early-onset preeclampsia was reduced by 89% (pooled odds ratio [OR] = 0.11, 95% confidence interval [CI]: 0.01–0.93, p = 0.04) in women with thrombophilia, the incidence of SGA neonates below the 5th percentile by 48% (pooled OR = 0.52, 95% CI: 0.28–0.96, p = 0.04) in women with a history of preeclampsia and/or SGA neonates, and the incidence of SGA neonates below the 10th percentile by 31% (pooled OR = 0.69, 95% CI: 0.50–0.96, p = 0.03) in the whole population.

Conclusion Concerning the whole studied population, combined anticoagulant therapy is not superior to aspirin alone. However, it may be more effective in preventing early-onset preeclampsia regarding women with thrombophilia, SGA neonates below the 5th percentile regarding women with a history of preeclampsia and/or SGA, and SGA neonates below the 10th percentile in moderate- or high-risk women. The above mixed but promising results need to be envisaged with caution due to the clinical heterogeneity of the included studies which is the main limitation of our research. Nevertheless, the strict and narrow inclusion search criteria, and the appropriate subgroup analysis are its main strengths. More RCTs with homogeneous populations and stricter inclusion criteria are needed to confirm these results.

Key Points

• Combined therapy is not superior to aspirin alone.

• Combined therapy in women with thrombophilia may protect against early-onset preeclampsia.

• Combined therapy in moderate/high-risk women may protect against SGA <10th percentile neonates.

Registration and Protocol

This study is registered with PROSPERO, number: CRD42020148500 ( https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=148500 ). The revised version of our protocol is likewise registered at: https://www.protocols.io/view/the-combination-of-lmwh-low-molecular-weight-hepar-bhdtj26n with the following DOI number: 10.17504/protocols.io.bhdtj26n.

Publication History

Received: 12 August 2021

Accepted: 17 February 2022

Accepted Manuscript online:
02 March 2022

Article published online:
22 August 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

• References

• 1 Espinoza J, Vidaeff A, Pettker CM, Simhan H. ACOG practice bulletin no. 202: gestational hypertension and preeclampsia. Obstet Gynecol 2019; 133 (01) 1
  PubMedGoogle Scholar
• 2 Steegers EAPA, Von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. 2010; 376: 631-644
  PubMedGoogle Scholar
• 3 Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet 2006; 367 (9516): 1066-1074
  CrossrefPubMedGoogle Scholar
• 4 Habiba M, Heyn R, Bianchi P, Brosens I, Benagiano G. The development of the human uterus: morphogenesis to menarche. Hum Reprod Update 2021; 27 (01) 1-26
  CrossrefPubMedGoogle Scholar
• 5 Villar J, Carroli G, Wojdyla D. et al; World Health Organization Antenatal Care Trial Research Group. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions?. Am J Obstet Gynecol 2006; 194 (04) 921-931
  CrossrefPubMedGoogle Scholar
• 6 Ma'ayeh M, Rood KM, Kniss D, Costantine MM. Novel interventions for the prevention of preeclampsia. Curr Hypertens Rep 2020; 22 (02) 17
  CrossrefPubMedGoogle Scholar
• 7 LeFevre ML. U.S. Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014; 161 (11) 819-826
  CrossrefPubMedGoogle Scholar
• 8 Choi YJ, Shin S. Aspirin prophylaxis during pregnancy: a systematic review and meta-analysis. Am J Prev Med 2021; 61 (01) e31-e45
  CrossrefPubMedGoogle Scholar
• 9 Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol 2018; 218 (03) 287-293.e1
  CrossrefPubMedGoogle Scholar
• 10 Roberge S, Demers S, Nicolaides KH, Bureau M, Côté S, Bujold E. Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysis. Ultrasound Obstet Gynecol 2016; 47 (05) 548-553
  CrossrefPubMedGoogle Scholar
• 11 Duley L, Meher S, Hunter KE, Seidler AL, Askie LM. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2019;2019(10)
  PubMedGoogle Scholar
• 12 ACOG committee opinion no. 743: low-dose aspirin use during pregnancy. Obstet Gynecol 2018; 132 (01) e44-e52
  CrossrefPubMedGoogle Scholar
• 13 NICE. Hypertension in pregnancy: diagnosis and management. Accessed September 5, 2019 at: https://www.nice.org.uk/guidance/ng133/chapter/Recommendations#reducing-the-risk-of-hypertensive-disorders-in-pregnancy
  PubMedGoogle Scholar
• 14 Ghesquière L, Clouqueur E, Garabedian C, Tsatsaris V, Houfflin-Debarge V. Can we prevent preeclampsia? [in French]. Presse Med 2016; 45 (4, pt. 1): 403-413
  PubMedGoogle Scholar
• 15 Gris JC, Chauleur C, Molinari N. et al. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. Thromb Haemost 2011; 106 (06) 1053-1061
  PubMedGoogle Scholar
• 16 Gris JC, Chauleur C, Faillie JL. et al. Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial. Thromb Haemost 2010; 104 (04) 771-779
  PubMedGoogle Scholar
• 17 Rey E, Garneau P, David M. et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 2009; 7 (01) 58-64
  CrossrefPubMedGoogle Scholar
• 18 Martinelli I, Ruggenenti P, Cetin I. et al; HAPPY Study Group. Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood 2012; 119 (14) 3269-3275
  CrossrefPubMedGoogle Scholar
• 19 Rodger MA, Carrier M, Le Gal G. et al; Low-Molecular-Weight Heparin for Placenta-Mediated Pregnancy Complications Study Group. Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood 2014; 123 (06) 822-828
  CrossrefPubMedGoogle Scholar
• 20 Rodger MA, Gris J-C, de Vries JIP. et al; Low-Molecular-Weight Heparin for Placenta-Mediated Pregnancy Complications Study Group. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet 2016; 388 (10060): 2629-2641
  CrossrefPubMedGoogle Scholar
• 21 Dodd JM, McLeod A, Windrim RC, Kingdom J. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev 2013; 2013 (07) CD006780
  PubMedGoogle Scholar
• 22 de Vries JIP, van Pampus MG, Hague WM, Bezemer PD, Joosten JH. FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost 2012; 10 (01) 64-72
  CrossrefPubMedGoogle Scholar
• 23 Groom KM, McCowan LM, Mackay LK. et al; Enoxaparin for Prevention of Preeclampsia and Intrauterine Growth Restriction Trial Investigator Group. Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial. Am J Obstet Gynecol 2017; 216 (03) 296.e1-296.e14
  CrossrefPubMedGoogle Scholar
• 24 Haddad B, Winer N, Chitrit Y. et al; Heparin-Preeclampsia (HEPEPE) Trial Investigators. Enoxaparin and aspirin compared with aspirin alone to prevent placenta-mediated pregnancy complications: a randomized controlled trial. Obstet Gynecol 2016; 128 (05) 1053-1063
  CrossrefPubMedGoogle Scholar
• 25 Hypertension in Pregnancy: Diagnosis and Management. NICE Guideline. Available at: Hypertension in pregnancy: diagnosis and management (nice.org.uk). Accessed March 21, 2022
  PubMedGoogle Scholar
• 26 Zeve D, Regelmann MO, Holzman IR, Rapaport R. Small at birth, but how small? the definition of SGA revisited. Horm Res Paediatr 2016; 86 (05) 357-360
  CrossrefPubMedGoogle Scholar
• 27 Maciejewski E, Hamon I, Fresson J, Hascoet J-M. Growth and neurodevelopment outcome in symmetric versus asymmetric small for gestational age term infants. J Perinatol 2016; 36 (08) 670-675
  CrossrefPubMedGoogle Scholar
• 28 Unterscheider J, Daly S, Geary MP. et al. Optimizing the definition of intrauterine growth restriction: the multicenter prospective PORTO study. Am J Obstet Gynecol 2013; 208 (04) 290.e1-290.e6
  CrossrefPubMedGoogle Scholar
• 29 Gomella TL, Cunningham MD, Eyal FG. Neonatology. In: Gomella TL, Cunningham MD, Eyal FG, Tuttle DJ. eds. Neonatology: Management, Procedures, On-Call Problems, Diseases, and Drugs. 7th ed.. New York, NY: McGraw-Hill; 2013: 732-742
  Google Scholar
• 30 Blencowe H, Cousens S, Oestergaard MZ. et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 2012; 379 (9832): 2162-2172
  CrossrefPubMedGoogle Scholar
• 31 Engle WA, Tomashek KM, Wallman C. Committee on Fetus and Newborn, American Academy of Pediatrics. “Late-preterm” infants: a population at risk. Pediatrics 2007; 120 (06) 1390-1401
  CrossrefPubMedGoogle Scholar
• 32 MacDorman MF, Gregory ECW. Fetal and perinatal mortality: United States, 2013. Natl Vital Stat Rep 2015; 64 (08) 1-24
  PubMedGoogle Scholar
• 33 Pineles BL, Hsu S, Park E, Samet JM. Systematic review and meta-analyses of perinatal death and maternal exposure to tobacco smoke during pregnancy. Am J Epidemiol 2016; 184 (02) 87-97
  CrossrefPubMedGoogle Scholar
• 34 McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol 2016; 75: 40-46
  CrossrefPubMedGoogle Scholar
• 35 Cochrane effective practice and organization of care (EPOC). Available at: Cochrane Effective Practice and Organisation of Care (EPOC)—Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) (ox.ac.uk). Accessed March 21, 2022
  PubMedGoogle Scholar
• 36 American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122 (05) 1122-1131
  CrossrefPubMedGoogle Scholar
• 37 Engle WA, Tomashek KM, Wallman C. Committee on Fetus and Newborn, American Academy of Pediatrics. “Late-preterm” infants: a population at risk. Pediatrics 2007; 120 (06) 1390-1401
  CrossrefPubMedGoogle Scholar
• 38 Sterne JAC, Hernán MA, McAleenan A, Reeves BC, Higgins JPT. Chapter 25: Assessing risk of bias in a non-randomized study. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. (editors) Cochrane Handbook for Systematic Reviews of Interventions version 6.0. Cochrane. Chichester, the United Kingdom: John Wiley & Sons; 2019
  Google Scholar
• 39 Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. (editors) Cochrane Handbook for Systematic Reviews of Interventions version 6.0. Cochrane. Chichester, the United Kingdom: John Wiley & Sons; 2019
  Google Scholar
• 40 McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 2021; 12 (01) 55-61
  CrossrefPubMedGoogle Scholar
• 41 Schünemann H, Brozek J, Guyatt G, Oxman A. editors GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available from https://gdt.gradepro.org/app/handbook/handbook.html
  PubMedGoogle Scholar
• 42 GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime, 2021. Available from gradepro.org.
  PubMed
• 43 Granger KA, Farquharson RG. Obstetric outcome in antiphospholipid syndrome. Lupus 1997; 6 (06) 509-513
  CrossrefPubMedGoogle Scholar
• 44 Merviel P, Cabry R, Lourdel E. et al. Comparison of two preventive treatments for patients with recurrent miscarriages carrying a C677T methylenetetrahydrofolate reductase mutation: 5-year experience. J Int Med Res 2017; 45 (06) 1720-1730
  CrossrefPubMedGoogle Scholar
• 45 Riyazi N, Leeda M, de Vries JI, Huijgens PC, van Geijn HP, Dekker GA. Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur J Obstet Gynecol Reprod Biol 1998; 80 (01) 49-54
  CrossrefPubMedGoogle Scholar
• 46 Neykova K, Dimitrova V, Dimitrov R. The effect of antithrombotic therapy on the recurrence of placenta-mediated diseases in pregnancy. J Matern Fetal Neonatal Med 2020; 1-7
  PubMedGoogle Scholar
• 47 Sergio F, Maria Clara D, Gabriella F, Giorgia S, Giancarlo P, Alessandro C. Sara De Carolis. Prophylaxis of recurrent preeclampsia: low-molecular-weight heparin plus low-dose aspirin versus low-dose aspirin alone. Hypertens Pregnancy 2006; 25 (02) 115-127
  CrossrefPubMedGoogle Scholar
• 48 Mohamed KAA, Saad AS. Enoxaparin and aspirin therapy for recurrent pregnancy loss due to anti-phospholipid syndrome (APS). Middle East Fertil Soc J 2014; 19 (03) 176-182
  CrossrefPubMedGoogle Scholar
• 49 Kalk JJ, Huisjes AJM, de Groot CJM. et al. Recurrence rate of pre-eclampsia in women with thrombophilia influenced by low-molecular-weight heparin treatment?. Neth J Med 2004; 62 (03) 83-87
  PubMedGoogle Scholar
• 50 Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002; 100 (03) 408-413
  PubMedGoogle Scholar
• 51 Laskin CA, Spitzer KA, Clark CA. et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009; 36 (02) 279-287
  CrossrefPubMedGoogle Scholar
• 52 Gris J-C, Chauleur C, Molinari N. et al. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. Thromb Haemost 2011; 106 (06) 1053-1061
  PubMedGoogle Scholar
• 53 Elmahashi MO, Elbareg AM, Essadi FM, Ashur BM, Adam I. Low dose aspirin and low-molecular-weight heparin in the treatment of pregnant Libyan women with recurrent miscarriage. BMC Res Notes 2014; 7 (01) 23
  CrossrefPubMedGoogle Scholar
• 54 Karadağ C, Akar B, Gönenç G, Aslancan R, Yılmaz N, Çalışkan E. Aspirin, low molecular weight heparin, or both in preventing pregnancy complications in women with recurrent pregnancy loss and factor V Leiden mutation. J Matern Fetal Neonatal Med 2020; 33 (11) 1934-1939
  CrossrefPubMedGoogle Scholar
• 55 Kaandorp SP, Goddijn M, van der Post JAM. et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010; 362 (17) 1586-1596
  CrossrefPubMedGoogle Scholar
• 56 Visser J, Ulander V-M, Helmerhorst FM. et al. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial. Thromb Haemost 2011; 105 (02) 295-301
  Article in Thieme ConnectPubMedGoogle Scholar
• 57 van Hoorn ME, Hague WM, van Pampus MG, Bezemer D, de Vries JIP. FRUIT Investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. Eur J Obstet Gynecol Reprod Biol 2016; 197: 168-173
  CrossrefPubMedGoogle Scholar
• 58 Ferrier C, Koferl U, Durig P, Schneider H. LMW-heparin and low-dose aspirin for prevention of preeclampsia: preliminary data of a randomized prospective study. Hypertens Pregnancy 2000; 19 (01) 82
  PubMedGoogle Scholar
• 59 North RA, Ferrier C, Gamble G, Fairley KF, Kincaid-Smith P. Prevention of preeclampsia with heparin and antiplatelet drugs in women with renal disease. Aust N Z J Obstet Gynaecol 1995; 35 (04) 357-362
  CrossrefPubMedGoogle Scholar
• 60 Lima F, Khamashta MA, Buchanan NM, Kerslake S, Hunt BJ, Hughes GR. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996; 14 (02) 131-136
  PubMedGoogle Scholar
• 61 Bar J, Mashiah R, Cohen-Sacher B. et al. Effect of thrombophylaxis on uterine and fetal circulation in pregnant women with a history of pregnancy complications. Thromb Res 2001; 101 (04) 235-241
  CrossrefPubMedGoogle Scholar
• 62 Franklin RD, Kutteh WH. Antiphospholipid antibodies (APA) and recurrent pregnancy loss: treating a unique APA positive population. Hum Reprod 2002; 17 (11) 2981-2985
  CrossrefPubMedGoogle Scholar
• 63 Leduc L, Dubois E, Takser L, Rey E, David M. Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. J Obstet Gynaecol Can 2007; 29 (10) 787-793
  CrossrefPubMedGoogle Scholar
• 64 Gris JC, Bouvier S, Molinari N. et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood 2012; 119 (11) 2624-2632
  CrossrefPubMedGoogle Scholar
• 65 Shinozaki N, Ebina Y, Deguchi M, Tanimura K, Morizane M, Yamada H. Protein S deficiency complicated pregnancy in women with recurrent pregnancy loss. Gynecol Endocrinol 2016; 32 (08) 672-674
  CrossrefPubMedGoogle Scholar
• 66 Abheiden CNH, Blomjous BS, Kroese SJ. et al. Low-molecular-weight heparin and aspirin use in relation to pregnancy outcome in women with systemic lupus erythematosus and antiphospholipid syndrome: A cohort study. Hypertens Pregnancy 2017; 36 (01) 8-15
  CrossrefPubMedGoogle Scholar
• 67 Yoshihara H, Sugiura-Ogasawara M, Kitaori T, Katano K, Ozaki Y. Danaparoid is effective and safe for patients with obstetric antiphospholipid syndrome. Mod Rheumatol 2020; 30 (02) 332-337
  CrossrefPubMedGoogle Scholar
• 68 Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174 (05) 1584-1589
  CrossrefPubMedGoogle Scholar
• 69 Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314 (7076): 253-257
  CrossrefPubMedGoogle Scholar
• 70 Goel N, Tuli A, Choudhry R. The role of aspirin versus aspirin and heparin in cases of recurrent abortions with raised anticardiolipin antibodies. Med Sci Monit 2006; 12 (03) CR132-CR136
  PubMedGoogle Scholar
• 71 Giancotti A, La Torre R, Spagnuolo A. et al. Efficacy of three different antithrombotic regimens on pregnancy outcome in pregnant women affected by recurrent pregnancy loss. J Matern Fetal Neonatal Med 2012; 25 (07) 1191-1194
  CrossrefPubMedGoogle Scholar
• 72 Bao SH, Sheng SL, Liao H, Zhou Q, Frempong ST, Tu WY. Use of D-dimer measurement to guide anticoagulant treatment in recurrent pregnancy loss associated with antiphospholipid syndrome. Am J Reprod Immunol 2017; 78 (06) e12770
  CrossrefPubMedGoogle Scholar
• 73 Lecarpentier E, Gris JC, Cochery-Nouvellon E. et al. Angiogenic factor profiles in pregnant women with a history of early-onset severe preeclampsia receiving low-molecular-weight heparin prophylaxis. Obstet Gynecol 2018; 131 (01) 63-69
  CrossrefPubMedGoogle Scholar
• 74 Bar J, Cohen-Sacher B, Hod M, Blickstein D, Lahav J, Merlob P. Low-molecular-weight heparin for thrombophilia in pregnant women. Int J Gynaecol Obstet 2000; 69 (03) 209-213
  CrossrefPubMedGoogle Scholar
• 75 Corrigendum to Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: The FRUIT-RCT. J Thromb Haemost 2012; 10 (01) 64-72
  CrossrefPubMedGoogle Scholar
• 76 Visser J, Ulander VM, Helmerhorst FM. et al. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial. Thromb Haemost 2011; 105 (02) 295-301
  Article in Thieme ConnectPubMedGoogle Scholar
• 77 Sobel ML, Kingdom J, Drewlo S. Angiogenic response of placental villi to heparin. Obstet Gynecol 2011; 117 (06) 1375-1383
  CrossrefPubMedGoogle Scholar
• 78 Sela S, Natanson-Yaron S, Zcharia E, Vlodavsky I, Yagel S, Keshet E. Local retention versus systemic release of soluble VEGF receptor-1 are mediated by heparin-binding and regulated by heparanase. Circ Res 2011; 108 (09) 1063-1070
  CrossrefPubMedGoogle Scholar
• 79 Infante-Rivard C, David M, Gauthier R, Rivard G-E. Lupus anticoagulants, anticardiolipin antibodies, and fetal loss. A case-control study. N Engl J Med 1991; 325 (15) 1063-1066
  CrossrefPubMedGoogle Scholar
• 80 Lockshin MD. Pregnancy loss in the antiphospholipid syndrome. Thromb Haemost 1999; 82 (02) 641-648
  PubMedGoogle Scholar
• 81 de Jong PG, Goddijn M, Middeldorp S. Testing for inherited thrombophilia in recurrent miscarriage. Semin Reprod Med 2011; 29 (06) 540-547
  Article in Thieme ConnectPubMedGoogle Scholar
• 82 Laude I, Rongières-Bertrand C, Boyer-Neumann C. et al. Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight. Thromb Haemost 2001; 85 (01) 18-21
  Article in Thieme ConnectPubMedGoogle Scholar
• 83 Isermann B, Sood R, Pawlinski R. et al. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med 2003; 9 (03) 331-337
  CrossrefPubMedGoogle Scholar
• 84 Grandone E, Villani M, Tiscia GL. Aspirin and heparin in pregnancy. Expert Opin Pharmacother 2015; 16 (12) 1793-1803
  CrossrefPubMedGoogle Scholar
• 85 Haddad B, Lecarpentier E, Touboul C, Sibai BM. Low-molecular-weight heparin for the prevention of placenta-mediated pregnancy complications. Clin Obstet Gynecol 2016; 60 (01) 153-160
  CrossrefPubMedGoogle Scholar
• 86 de Jong PG, Kaandorp S, Di Nisio M, Goddijn M, Middeldorp S. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database Syst Rev 2014; 2014 (07) CD004734
  CrossrefPubMedGoogle Scholar
• 87 Hamulyák EN, Scheres LJJ, Marijnen MC, Goddijn M, Middeldorp S. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database Syst Rev 2020; 5 (05) CD012852
  PubMedGoogle Scholar
• 88 Li J, Gao YH, Xu L, Li ZY. Meta-analysis of heparin combined with aspirin versus aspirin alone for unexplained recurrent spontaneous abortion. Int J Gynaecol Obstet 2020; 151 (01) 23-32
  CrossrefPubMedGoogle Scholar
• 89 Lin T, Chen Y, Cheng X, Li N, Sheng X. Enoxaparin (or plus aspirin) for the prevention of recurrent miscarriage: a meta-analysis of randomized controlled studies. Eur J Obstet Gynecol Reprod Biol 2019; 234: 53-57
  CrossrefPubMedGoogle Scholar
• 90 Areia AL, Fonseca E, Areia M, Moura P. Low-molecular-weight heparin plus aspirin versus aspirin alone in pregnant women with hereditary thrombophilia to improve live birth rate: meta-analysis of randomized controlled trials. Arch Gynecol Obstet 2016; 293 (01) 81-86
  CrossrefPubMedGoogle Scholar
• 91 Lu C, Liu Y, Jiang HL. Aspirin or heparin or both in the treatment of recurrent spontaneous abortion in women with antiphospholipid antibody syndrome: a meta-analysis of randomized controlled trials. J Matern Fetal Neonatal Med 2019; 32 (08) 1299-1311
  CrossrefPubMedGoogle Scholar
• 92 Liu X, Qiu Y, Yu ED. et al. Comparison of therapeutic interventions for recurrent pregnancy loss in association with antiphospholipid syndrome: A systematic review and network meta-analysis. Am J Reprod Immunol 2020; 83 (04) e13219
  CrossrefPubMedGoogle Scholar
• 93 Yang Z, Shen X, Zhou C, Wang M, Liu Y, Zhou L. Prevention of recurrent miscarriage in women with antiphospholipid syndrome: a systematic review and network meta-analysis. Lupus 2021; 30 (01) 70-79
  CrossrefPubMedGoogle Scholar
• 94 Jacobson B, Rambiritch V, Paek D. et al. Safety and efficacy of enoxaparin in pregnancy: a systematic review and meta-analysis. Adv Ther 2020; 37 (01) 27-40
  CrossrefPubMedGoogle Scholar
• 95 Lefkou E, Mamopoulos A, Fragakis N. et al. Clinical improvement and successful pregnancy in a preeclamptic patient with antiphospholipid syndrome treated with pravastatin. Hypertension 2014; 63 (05) e118-e119
  CrossrefPubMedGoogle Scholar
• 96 Costantine MM, Cleary K, Hebert MF. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Units Network. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol 2016; 214 (06) 720.e1-720.e17
  CrossrefPubMedGoogle Scholar

• Supplementary Material